Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn-s disease: data from CALM - Panaccione, R.; Colombel, J-F.; Bossuyt, P.; Baert, F.; Vanasek, T.; Danalioglu, A.; Novacek, G.; Armuzzi, A.; Reinisch, W.; Neimark, E.; Petersson, J.; Robinson, M.; et al. (My University, 2018)